Accepted for Publication: December 27, 2022.
Published Online: February 22, 2023. doi:10.1001/jamadermatol.2022.6266
Corresponding Author: Helen Bui, MD, UNC Hospitals, 101 Manning Drive, Chapel Hill, NC 27514 (firstname.lastname@example.org).
Author Contributions: Drs Bui and Sayed had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Bui, Bechara, George, Goldberg, Saylor, Sayed.
Acquisition, analysis, or interpretation of data: Bui, Bechara, George, Goldberg, Hamzavi, Kirby, Sayed.
Drafting of the manuscript: Bui, Bechara, Hamzavi, Saylor, Sayed.
Critical revision of the manuscript for important intellectual content: Bui, Bechara, George, Goldberg, Hamzavi, Kirby, Sayed.
Statistical analysis: Bui.
Administrative, technical, or material support: Bui, Bechara, Goldberg, Hamzavi, Sayed.
Supervision: Bechara, Goldberg, Kirby, Sayed.
Conflict of Interest Disclosures: Dr George reported personal fees from AbbVie unrelated to topic outside the submitted work. Dr Hamzavi reported personal fees from Incyte, Abbvie, grants from Pfizer, personal fees from UCB, Jansen, Boerhinger Ingelheim, Novartis, and nonfinancial support from Lenicura during the conduct of the study. Dr Kirby reported personal fees from AbbVie, ChemoCentryx, grants from Incyte, personal fees from Janssen, Novartis, and UCB outside the submitted work. Dr Sayed reported grants from AbbVie Education grant, investigator fees to institution, personal fees from AbbVie speaking, consulting, personal fees from Novartis Speaking, consulting, grants from Novartis Investigator fees paid to institution, grants from UCB Investigator fees paid to institution, personal fees from UCB Consulting fees, grants from Incyte Investigational fees paid to institution, grants from Chemocentryx Investigator fees paid to institution, grants from InflaRx Investigator fees paid to institution, personal fees from InflaRx Consulting, and personal fees from Amaris Consulting outside the submitted work; and I am a directing member of the HS Foundation. No other disclosures were reported.
Funding/Support: National Institute of Health, National Institute of Arthritis, Musculoskeletal, and Skin Diseases grant number 1R21AR075996-01A1. We thank the National Institute of Health, National Institute of Arthritis, Musculoskeletal, and Skin Diseases grant number 1R21AR075996-01A1 for supporting the design and conduct of the study; collection, management, analysis, and interpretation of the data.
Role of the Funder/Sponsor: The National Institute of Health and the National Institute of Arthritis, Musculoskeletal, and Skin Diseases had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
LAV , Nguyen
TV , Damiani
G , Sayed
C , Jemec
GBE , Hamzavi
I . Medical and surgical management of hidradenitis suppurativa: a review of international treatment guidelines and implementation in general dermatology practice. Dermatology
. 2020;236(5):393-412. doi:10.1159/000507323
A , Sayed
C , Alavi
et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol
. 2019;81(1):76-90. doi:10.1016/j.jaad.2019.02.067
A , Sayed
C , Alavi
et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol
. 2019;81(1):91-101. doi:10.1016/j.jaad.2019.02.068
S , Nazzaro
G , Grancini
et al. Lymph node involvement in axillary hidradenitis suppurativa: a clinical, ultrasonographic and bacteriological study conducted during radical surgery. J Clin Med
. 2021;10(7):1433. doi:10.3390/jcm10071433
LS , Kueberuwa
E , Beederman
M , Gottlieb
LJ . Wide excision and healing by secondary intent for the surgical treatment of hidradenitis suppurativa: A single-center experience. J Plast Reconstr Aesthet Surg
. 2016;69(4):554-566. doi:10.1016/j.bjps.2015.12.004
ZN , Zugaj
M , Jacobs
W , van der Horst
CMAM , Lapid
O . Recurrence rates following reconstruction strategies after wide excision of hidradenitis suppurativa: a systematic review and meta-analysis. Dermatol Surg
. 2021;47(4):e106-e110. doi:10.1097/DSS.0000000000002815
ZN , Bartelink
SAW , Hadi
K , van de Kar
AL , van der Horst
CMAM , Lapid
O . A multicenter analysis of wide excision and reconstruction for severe anogenital hidradenitis suppurativa. Ann Plast Surg
. 2021;86(2):193-200. doi:10.1097/SAP.0000000000002554
E , Pawliwec
A , Alavi
A , George
R . The surgeon’s perspective: a retrospective study of wide local excisions taken to healthy subcutaneous fat in the management of advanced hidradenitis suppurativa. Can J Surg
. 2020;63(2):E94-E99. doi:10.1503/cjs.003119
O , Hasdemir
AO , Kahramansoy
N , Çöl
C , Erkol
H . Surgical approach to extensive hidradenitis suppurativa. Dermatol Surg
. 2011;37(6):835-842.PubMedGoogle Scholar
JW , Jiang
CS , Singh
et al. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data. J Am Acad Dermatol
. 2020;82(5):1150-1157. doi:10.1016/j.jaad.2019.12.044
DH , Shukla
RK , Delbecq
AL , Walster
GW . A comparative study of differences in subjective likelihood estimates made by individuals, interacting groups, Delphi groups, and nominal groups. Organ Behav Hum Perform
. 1973;9:280-291. doi:10.1016/0030-5073(73)90052-4
Qualtrics [computer program]. Version January 2021. Provo, Utah, USA2021.
JL , Spoo
JR , Leeman
FWJ , Jonkman
MF , Horváth
B . Skin-tissue-sparing excision with electrosurgical peeling (STEEP): a surgical treatment option for severe hidradenitis suppurativa Hurley stage II/III. J Eur Acad Dermatol Venereol
. 2015;29(2):379-382. doi:10.1111/jdv.12376